May 12, 2017 at 14:00
B237 seminar room (ground floor), Arrhenius Laboratories, Svante Arrhenius väg 16, Stockholm University

The Department of Environmental Science and Analytical Chemistry (ACES) at Stockholm University organizes a special seminar on Advances in MALDI Imaging Mass Spectrometry and its applications on drug discovery

Abstract
Matrix-assisted laser desorption/ionization imaging mass spectrometry (MALDI IMS) is becoming increasingly important in drug discovery for determining the distribution of drugs and their metabolites in preclinical tissues. Imaging MS has an advantage over other imaging modalities in that it does not require the use of a radiolabel or target specific antibodies or reagents. In addition, MALDI IMS provides unique molecular specificity and is amenable to a wide range of analytes, from low molecular weight drugs to proteins. Furthermore, the spatial distribution of the molecular images obtained easily correlate with microscopy and other imaging techniques. In this presentation, examples using MALDI IMS in the discovery environment, including ophthalmology, oncology, infectious diseases, and neuroscience will be presented.  Emphasis will be placed on advances in MALDI IMS instrumentation that have resulted in much higher mass resolution, spatial resolution, and sensitivity.  Examples of how these advances enable the drug discovery scientist to explore early toxicology and pharmacology findings will be discussed.   
Patrick’s Bio
Patrick J. Rudewicz received his B.A. degree in Chemistry from Gettysburg College and his Ph.D. in Analytical Chemistry from the University of Delaware under the direction of Professor Burnaby Munson, co-inventor of Chemical Ionization Mass Spectrometry.  After graduation, he was a Post-Doctoral Fellow at Smith Kline where he developed the methodology of on-line LC/MS/MS for the structural characterization of drug metabolites in biological matrices.  Dr. Rudewicz then worked at Thermo where he managed their MS applications laboratory in Tokyo, Japan.  Since then he has held positions of increasing responsibility within the pharmaceutical industry, including Associate Director DMPK at Genentech and Director DMPK at Elan Pharmaceuticals.  He presently is Head, Analytics and Imaging MS, at Novartis Institute for Biomedical Research in Emeryville, CA.
Coffee mingle afterwards
Welcome!
Please sign up in the following form and indicate dietary preferences. 
 
For queries, please contact:
Sophia Theodorou
sophy.theodorou@gmail.com
Mob: 0722960299
 ​